Inclusion Criteria:  Patients ≥ 18 and ≤75 years with type 1 diabetes; Diagnosed as T1DM ≥ 12 months before enrollment in the study; HbA1c ≥ 7.0 to ≤10.0%; Receipt of basal plus pre-prandial insulin and/or oral anti-diabetic agents ≥ 12 weeks before enrollment in the study; BMI ≤ 35kg / m2.  Exclusion Criteria:  Patients with any of the following conditions will be excluded: Pregnant or lactating women Severe hypoglycemia within one month; Myocardial infarction, stroke or other severe cardiovascular events within 6 months prior to informed consent Receipt of Sulfonylureas, Meglitinides derivatives, Thiazolidinediones, Dpp-4 inhibitors or GLP-1 agonists within 3 months prior to informed consent; Current treatment with systemic steroids or immunosuppressive agents, or have immunologic deficiency disease at time of informed consent Severe mental instability, or alcohol abuse, or drug abuse Cancer within 5 years prior to informed consent Pancreatitis of severe infectious diseases within 1 months prior to informed consent Known hypersensitivity or allergy to the insulin Renal impairment (CKD-EPI eGFR<60ml/min) Impaired hepatic function, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined Participation in another trial within 2 months prior to informed consent Patients that investigators believe may fail to complete the study